Skip to main content
Clinical Trials/NCT07603726
NCT07603726CompletedNot Applicable

Multimodal Nutraceutical and Psychological Intervention for GGT Reduction in Individuals With Alcohol Use Disorder

Medical Center TOPMED1 site in 1 country197 target enrollmentStarted: January 1, 2024Last updated:

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
197
Locations
1

Study Overview

Brief Summary

The aim of this clinical trial is to evaluate whether a combined nutraceutical and psychological intervention can reduce gamma-glutamyl transferase (GGT) levels in individuals with Alcohol Use Disorder (AUD).

The main question it seeks to answer is:

• Does this combined intervention lead to a reduction in GGT levels over time? Participants with Alcohol Use Disorder and elevated GGT levels were included in the study.

Participants will:

  • Receive nutraceutical supplements aimed at supporting liver function
  • Participate in psychological support sessions to help reduce alcohol consumption
  • Have their GGT levels monitored over time.

Detailed Description

Alcohol Use Disorder (AUD) is commonly associated with liver dysfunction, which can be reflected by elevated levels of gamma-glutamyl transferase (GGT). Monitoring changes in GGT levels may provide useful information about liver status and response to interventions aimed at reducing alcohol-related harm.

This study evaluates a multimodal approach that combines nutraceutical support with psychological intervention in individuals with AUD and elevated GGT levels. The rationale for this combined approach is to address both the biological and behavioral components of alcohol use.

Participants were included based on the presence of Alcohol Use Disorder and elevated baseline GGT levels. For analysis purposes, participants were stratified according to baseline GGT values (55-99 U/L and ≥100 U/L).

The study focuses on assessing changes in GGT levels over time following the intervention. Additional analyses explore variations in response based on baseline GGT levels.

This study aims to contribute to the understanding of integrated approaches for improving liver-related biomarkers in individuals with Alcohol Use Disorder.

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Parallel
Primary Purpose
Screening
Masking
Single (Participant)

Masking Description

This is an open-label study. No participants, investigators, or outcome assessors were blinded to group assignment.

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Adults aged 18 years or older
  • Diagnosis of Alcohol Use Disorder
  • Elevated baseline gamma-glutamyl transferase (GGT) levels
  • Ability to provide informed consent

Exclusion Criteria

  • Severe liver disease (e.g., cirrhosis or hepatic failure)
  • Severe psychiatric disorders interfering with participation
  • Current participation in another clinical study
  • Incomplete clinical or laboratory data

Investigators

Sponsor
Medical Center TOPMED
Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials